SCHEMBL404991

SCHEMBL404991

Cc1ccc(N)c(I)c1F

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.36
CYP3A4 P08684 5/20 0.36
ALDH1A1 P00352 4/20 0.36
TSHR P16473 2/20 0.36
CASP1 P29466 1/20 0.36
S100B P04271 1/20 0.32
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 1/20 0.31
CD44 P16070 1/20 0.31
MAPT P10636 1/20 0.30
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13617977 0.81 TDP1 (0.36) TDP1CYP3A4ALDH1A1TSHRCASP1
SCHEMBL12920752 0.79 ACHE (0.33)
SCHEMBL1425839 0.77 CYP3A4 (0.40) TDP1CYP3A4ALDH1A1TSHRCASP1
SCHEMBL9229801 0.75 CYP3A4 (0.39) TDP1CYP3A4ALDH1A1TSHRCASP1
SCHEMBL405898 0.75 CD44 (0.44) TDP1CYP3A4ALDH1A1TSHRCASP1
SCHEMBL3867828 0.75 ALDH1A1 (0.39) ALDH1A1
SCHEMBL16089553 0.75 ACHE (0.36)
SCHEMBL16805981 0.75 CYP3A4 (0.43) TDP1CYP3A4ALDH1A1TSHRCASP1
SCHEMBL24474070 0.71 TDP1 (0.36) TDP1CYP3A4ALDH1A1TSHRCASP1
SCHEMBL12228594 0.71 TSHR (0.36) TDP1CYP3A4ALDH1A1TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 TDP1 4213/4885CYP3A4 2376/4885ALDH1A1 1909/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 TDP1 4213/4885CYP3A4 2376/4885ALDH1A1 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.